reports
Deciphera Pharmaceuticals Inc: 1 director
A director at Deciphera Pharmaceuticals Inc sold 17,801 shares at 12.570USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
PNC PNC FINANCIAL SERVICES GROUP INC.
WLDN WILLDAN GROUP
MACK MERRIMACK PHARMACEUTICALS INC
INTC INTEL CORPORATION
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
FCF FIRST COMMONWEALTH FINANCIAL CORPORATION
EXPR EXPRESS INC.
EQR EQUITY RESIDENTIAL
EOG EOG RESOURCES INC.
CPRX CATALYST PHARMACEUTICALS
CNC CENTENE CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CAMP CALAMP CORP.
BANF BANCFIRST
ALGN ALIGN TECHNOLOGY INC.
NEWT NEWTEK BUSINESS SERVICES INC.
TREE LENDINGTREE INC.
SMMF SUMMIT FINANCIAL GROUP INC.
IMH IMPAC MORTGAGE HOLDINGS INC.
CDZI CADIZ INC.
ADES ADVANCED EMISSIONS SOLUTIONS
SNAP SNAP INC. CLASS A
NEE NEXTERA ENERGY
APPN INC.
DCPH APPIAN
MPB DECIPHERA PHARMACEUTICALS INC.
SYBT MID PENN BANCORP INC.
CSSE S.Y. BANCORP
GIM INC.
MGTA CHICKEN SOUP FOR THE SOUL ENTERTAINMENT INC
OPBK TEMPLETON GLOBAL INCOME FUND
FULC MAGENTA THERAPEUTICS
CCO OP BANCORP
CTVA FULCRUM THERAPEUTICS
ZYME CLEAR CHANNEL OUTDOOR HOLDINGS INC
PGEN CORTEVA
ZI INC.
ONEW ZYMEWORKS INC.
PLBY PRECIGEN INC
MYO ZOOMINFO TECHNOLOGIES INC.
VERA ONEWATER MARINE
XOS PLBY GROUP INC
TRST MYOMO
PDLB VERA THERAPEUTICS INC
APLD XOS INC
EMO TRUSTCO BANK CORP NY
HSAQ PONCE FINANCIAL GROUP INC.
MSGM APPLIED BLOCKCHAIN INC
CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
HEALTH SCIENCES ACQUISITIONS CORP 2
MOTORSPORT GAMES INC
- Jonathan Moreland
PNC PNC FINANCIAL SERVICES GROUP INC.
WLDN WILLDAN GROUP
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MACK MERRIMACK PHARMACEUTICALS INC
INTC INTEL CORPORATION
HSKA HESKA CORPORATION
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
FCF FIRST COMMONWEALTH FINANCIAL CORPORATION
EQR EQUITY RESIDENTIAL
EOG EOG RESOURCES INC.
CPRX CATALYST PHARMACEUTICALS
CMTL COMTECH TELECOMMUNICATIONS CORP.
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CAMP CALAMP CORP.
CALX CALIX NETWORKS
BANF BANCFIRST
NEWT NEWTEK BUSINESS SERVICES INC.
CVV CVD EQUIPMENT
TREE LENDINGTREE INC.
SMMF SUMMIT FINANCIAL GROUP INC.
CDZI CADIZ INC.
JNCE JOUNCE THERAPEUTICS
APPN APPIAN
DCPH DECIPHERA PHARMACEUTICALS INC.
MPB MID PENN BANCORP INC.
OPTN OPTINOSE
GIM TEMPLETON GLOBAL INCOME FUND
SRRK SCHOLAR ROCK HOLDING CORPORATION
OPBK OP BANCORP
NGM NGM BIOPHARMACEUTICALS
FULC FULCRUM THERAPEUTICS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ZYME ZYMEWORKS INC.
PGEN PRECIGEN INC
NREF NEXPOINT REAL ESTATE FINANCE
ZI INC.
RILY ZOOMINFO TECHNOLOGIES INC.
ALVR B. RILEY FINANCIAL
GMED ALLOVIR
HOWL GENOMED INC
MYO WEREWOLF THERAPEUTICS
XOS INC.
TRST MYOMO
APLD XOS INC
EMO TRUSTCO BANK CORP NY
HSAQ APPLIED BLOCKCHAIN INC
MSGM CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
HEALTH SCIENCES ACQUISITIONS CORP 2
MOTORSPORT GAMES INC
- Jonathan Moreland
XOMA XOMA
WLDN WILLDAN GROUP
SEAC SEACHANGE INTERNATIONAL INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MACK MERRIMACK PHARMACEUTICALS INC
HSKA HESKA CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
EQR EQUITY RESIDENTIAL
EOG EOG RESOURCES INC.
CMTL COMTECH TELECOMMUNICATIONS CORP.
BANF BANCFIRST
NEWT NEWTEK BUSINESS SERVICES INC.
CVV CVD EQUIPMENT
TZOO TRAVELZOO
CULP CULP INC.
TREE LENDINGTREE INC.
JELD JELD-WEN HOLDING INC.
APPN APPIAN
DCPH DECIPHERA PHARMACEUTICALS INC.
OPTN OPTINOSE
GIM TEMPLETON GLOBAL INCOME FUND
SRRK SCHOLAR ROCK HOLDING CORPORATION
LOVE LOVESAC
FULC FULCRUM THERAPEUTICS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ZYME ZYMEWORKS INC.
NREF NEXPOINT REAL ESTATE FINANCE
JYNT INC.
RILY THE JOINT
ALVR B. RILEY FINANCIAL
PCVX ALLOVIR
HQI VAXCYTE
FET HIREQUEST INC.
LIXT FORUM ENERGY TECHNOLOGIES
COIN LIXTE BIOTECHNOLOGY HOLDINGS
HOWL COINBASE GLOBAL
MYO INC.
XOS WEREWOLF THERAPEUTICS
TRST INC.
APLD MYOMO
HSAQ XOS INC
GLSI TRUSTCO BANK CORP NY
GCV APPLIED BLOCKCHAIN INC
HEALTH SCIENCES ACQUISITIONS CORP 2
GREENWICH LIFESCIENCES INC
THE GABELLI CONVERTIBLE AND INCOME SECURITIES FUND
INC.
- Jonathan Moreland
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WLK WESTLAKE CHEMICAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TGTX TG THERAPEUTICS INC.
SIG SIGNET JEWELERS LIMITED
SAIA SAIA INC.
RICK RCI HOSPITALITY HOLDINGS
RCKY ROCKY BRANDS
PFGC PERFORMANCE FOOD GROUP COMPANY
MKSI MKS INSTRUMENTS INC.
IRDM IRIDIUM COMMUNICATIONS INC.
IPAR INTER PARFUMS INC.
IDXX IDEXX LABORATORIES INC.
FRGI FIESTA RESTAURANT GROUP INC.
FOXF FOX FACTORY HOLDING CORP.
FGEN FIBROGEN INC.
CPS COOPER-STANDARD HOLDINGS INC.
CNCE CONCERT PHARMACEUTICALS
AEIS ADVANCED ENERGY INDUSTRIES INC.
EVER EVER GOTESCO RESOURCES & HOLDINGS INC.
MGM MGM RESORTS INTERNATIONAL
ODFL OLD DOMINION FREIGHT LINE INC.
THO THOR INDUSTRIES INC.
X UNITED STATES STEEL CORPORATION
CLF CLEVELAND-CLIFFS INC
DCPH DECIPHERA PHARMACEUTICALS INC.
RYTM RHYTHM PHARMACEUTICALS
WHD CACTUS INC
LOVE LOVESAC
TROX TRONOX HOLDINGS PLC
FOX FOX CORPORATION CLASS B
ZYXI ZYNEX
NOV NOV INC.
XPOF XPONENTIAL FITNESS
RAIN INC.
SGHT RAIN THERAPEUTICS INC
ROIV SIGHT SCIENCES INC
OMGA ROIVANT SCIENCES LTD
KMPH OMEGA THERAPEUTICS INC
GBLI KEMPHARM INC
GBLI HOLDINGS LLC
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
BLUE BLUEBIRD BIO INC.
SRDX SURMODICS INC.
MKTX MARKETAXESS HOLDINGS INC.
LUNA LUNA INNOVATIONS
IPAR INTER PARFUMS INC.
HES HESS CORPORATION
CNCE CONCERT PHARMACEUTICALS
CLMT CALUMET SPECIALTY PRODUCTS PARTNERS L.P.
CHGG CHEGG INC.
PATK PATRICK INDUSTRIES INC.
MPC. MADISON PACIFIC PROPERTIES INC. CL B
GRL TOREX GOLD RESOURCES INC.
ACLS AXCELIS TECHNOLOGIES INC.
ETH ETHAN ALLEN INTERIORS INC.
MAT MATTEL INC.
NRP NATURAL RESOURCE PARTNERS L.P.
USFD US FOODS HOLDING CORP.
INFU INFUSYSTEMS HOLDINGS INC.
INTT INTEST CORP.
PLBC PLUMAS BANCORP
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DCPH DECIPHERA PHARMACEUTICALS INC.
KRYS KRYSTAL BIOTECH INC
ETNB 89BIO
FRG FRANCHISE GROUP
COGT COGENT BIOSCIENCES INC
JAKK JAKKS PACIFIC INC.
CAG ANGIANG PORT
XPOF XPONENTIAL FITNESS
RAIN INC.
ATXS RAIN THERAPEUTICS INC
ACLX ASTRIA THERAPEUTICS INC
OMGA ARCELLX INC
ADEA OMEGA THERAPEUTICS INC
XPERI HLDG CORP
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Co...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences: Jefferies Healthcare Conference on June 9, 2022 at 10:00 AM ET in New York, NY JMP Securities Life Sciences Conference on June 15, 2022 at 10:00 AM ET in New York, NY A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at . A replay of both webcasts will be archived on the Company’s website for 90 d...
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update. “We have made significant progress on our 2022 goals so far this year, demonstrating our commercial success with QINLOCK®, strengthening our balance sheet, and rapidly advancing our potential best-in-class and first-in-class clinical-stage pipeline,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “The strong commercial launch of QINLOCK in Germany underscores the l...
Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Res...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 4, 2022, to discuss the Company’s financial results and provide a corporate update. The conference call may be accessed by dialing (877) 270-2148 (domestic) or (412) 902-6510 (international). A webcast of the conference call will be available in the “Events and Prese...
Deciphera Pharmaceuticals Announces Closing of Public Offering of Comm...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,501,239 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 9,748,761 shares of its common stock at an exercise price of $0.01 per share. The shares of common stock sold include 2,250,000 shares pursuant to the option granted by Deciphera to the u...
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Comm...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 5,251,239 shares of its common stock at a public offering price of $10.00 per share. In addition, in lieu of common stock to certain investors, Deciphera is offering pre-funded warrants to purchase 9,748,761 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, which equals...
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it intends to offer and sell $150,000,000 of shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock offered in the public offering....
Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Heal...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Tucker Kelly, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022 at 4:20 PM ET in Miami. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at . A replay of the webcast will be archived on the Company’s website for 90 days following the presentation. About Deciphera Pharmaceuticals Deciphera is a biopharma...
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. “I am immensely proud of our organization’s achievements in 2021 and believe that we are well positioned for long-term success as we work towards our expected milestones in 2022,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “While the unexpected results of the INTRIGUE study and subsequent restructuring at the end of last year were very difficult, w...
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Confer...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the following investor conferences: Guggenheim 2022 Oncology Virtual Conference on February 9, 2022 at 8:30 AM ET 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 3:40 PM ET A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at . A replay of both webcasts will be archived on the Company’s websit...
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 202...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, February 8, 2022, to discuss the Company’s financial results and provide a corporate update. The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 8293127. A webcast of th...
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 C...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation of results from the INTRIGUE Phase 3 study of QINLOCK (ripretinib) in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib at the American Society of Clinical Oncology (ASCO) Plenary Series Session. The presentation, which follows the announcement in November 2021 of the top-line results, is titled “INTRIGUE: A phase III, randomized, op...
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2022 milestones in conjunction with its presentation at the 40th Annual J.P. Morgan Healthcare Conference. The Company will webcast its presentation today at 9:00 AM ET at . “Deciphera is well-positioned as we enter 2022 with multiple high-value clinical programs and a successful commercial franchise in QINLOCK, all generated by our proven ...
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Mor...
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 9:00 AM ET. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at . A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.